Current Issues of Pharmacy and Medical Sciences

Does adiponectin play a role in gestational diabetes?

Current Issues in Pharmacy and Medical Sciences Vol. 26, No. 3, Pages 258-262


1 Chair and Department of Endocrinology, Medical University of Lublin

2 Department of Laboratory Diagnostics, Medical University of Lublin

DOI: 10.12923/j.2084-980X/26.3/a.03


Current literature provides contradictory information on the role of adiponectin (AdipoQ) in the course of gestational diabetes (GDM). The aim of the study was to measure AdipoQ concentration in blood of women with GDM and to find relationships between this adipokine and clinical and biochemical parameters. The study group included 50 women diagnosed with GDM between 24 and 28 weeks of gestation who underwent routine prenatal tests for GDM in compliance with the guidelines of the Polish Diabetes Association. All patients underwent clinical and laboratory evaluation at GDM diagnosis. Laboratory tests  included serum AdipoQ concentration, fasting glucose, fasting insulin, OGTT and lipid parameters in serum. AdipoQ concentrations did not differ significantly between the groups during gestation (p=0.7054). In the subgroup (2h glucose level in the OGTT 200 mg/dl) the concentration of AdipoQ tended to be decreased as compared to the remaining patients from the study and control groups, though the decline was insignificant (p=0.0541). The concentration of AdipoQ in the subgroup was about 20% lower than in the other patients from the study group. No correlations, except with the neonatal weight (r= - 0.29, p<0.05), were found between AdipoQ and the studied parameters. The GDM group showed significantly elevated fasting glucose, insulin, HOMA-IR values, total cholesterol, LDL-cholesterol and triglicerydes, as compared with the control group (p.05). These results lead to the conclusion that women with newly diagnosed and promptly treated GDM have normal adiponectin level. A negative correlation between AdipoQ level and the birth weight may suggest that this adipokine plays a role in the control of the birth weight especially in the incidence of macrosomia.

Files to download


adiponectin, gestational diabetes, insulin resistance, birth weight, macrosomia


  1. Basaran A.: Pregnancy-induced hyperlipoproteinemia: review of the literature. Reprod. Sci., 16, 5, 2009.
  2. Catalano P.M. et al.: Adiponectin in human pregnancy: implications for regulation of glucose and lipid metabolism. Diabetologia, 49, 7, 2006.
  3. Chandran M. et al.: Adiponectin: more than just another fat cell hormone? Diabetes Care, 26, 8, 2003.
  4. Di Cianni G. et al.: Normal glucose tolerance and gestational diabetes mellitus: what is in between? Diabetes Care, 30, 7, 2007.
  5. Dobiasova M., Frohlich J.: The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin. Biochem., 34, 583, 2001.
  6. Fain J.N. et al.: Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology, 145, 2273, 2004.  
  7. Gil-Campos M., Cañete R.R., Gil A.: Adiponectin, the missing link in insulin resistance and obesity. Clin. Nutr., 23, 963, 2004.
  8. Hotta K. et al.: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol., 20, 6, 2000.
  9. Hulver M.W. et al.: Ethnic differences in adiponectin levels. Metabolism, 53, 1, 2004.
  10. Hunt K.J. et al.: Postpartum screening following GDM: how well are we doing? Curr. Diab. Rep., 10, 235, 2010.
  11. Kajantie E. et al.: Cord plasma adiponectin: a 20-fold rise between 24 weeks gestation and term. J. Clin. Endocrinol. Metab., 89, 8, 2004.
  12. Karpe F.: Insulin resistance by adiponectin deficiency: is the action in skeletal muscle? Diabetes, 62,701, 2013.
  13. Kopp H.P. et al.: Effects of marked weight loss on plasma levels of adiponectin, markers of chronic subclinical inflammation and insulin resistance in morbidly obese women. Int. J. Obes. (Lond), 29, 7, 2005.
  14. Leary J., Pettitt D.J., Jovanovic L.: Gestational diabetes guidelines in a HAPO world. Best Pract. Res. Clin. Endocrinol. Metab., 24, 4, 2010.
  15. Lowe L.P. et al. Inflammatory mediators and glucose in pregnancy: results from a subset of the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study. J. Clin. Endocrinol. Metab., 95, 12, 2010.
  16. Matthews D.R. et al.: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28, 412, 1985.
  17. Mazaki-Tovi S. et al. Adiponectin multimers in maternal plasma. J. Matern. Fetal. Neonatal Med., 21, 11, 2008.
  18. Mazaki-Tovi S. et al. Maternal serum adiponectin multimers in gestational diabetes. J. Perinat. Med., 37, 6, 2009.
  19. McLachlan K.A. et al.: Do adiponectin, TNFalpha, leptin and CRP relate to insulin resistance in pregnancy? Studies in women with and without gestational diabetes, during and after pregnancy. Diabetes Metab. Res. Rev., 22, 2, 2006.
  20. Nanda S. et al.: Maternal serum adiponectin at 11 to 13 weeks of gestation in the prediction of macrosomia. Prenat. Diagn., 31, 5, 2011.
  21. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation,106, 3143, 2002.
  22. Nishihara M. et al.: Birth length is a predictor of adiponectin levels in Japanese young children. J. Pediatr. Endocrinol. Metab., 23, 9, 2010.
  23. Owecki M. et al.: Circulating serum adiponectin concentrations do not differ between obese and non-obese caucasians and are unrelated to insulin sensitivity. Horm. Metab. Res., 39, 1, 2007.
  24. Polskie Towarzystwo Diabetologiczne: Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę. Diabetol. Prakt., 12, supl A, 2011.
  25. Retnakaran R. et al.: Impaired glucose tolerance of pregnancy is a heterogeneous metabolic disorder as defined by the glycemic response to the oral glucose tolerance test. Diabetes Care, 29, 1, 2006.
  26. Retnakaran R. et al.: Reduced adiponectin concentration in women with gestational diabetes: a potential factor in progression to type 2 diabetes. Diabetes Care, 27, 799, 2004.
  27. Retnakaran R., et al.: Ethnicity modifies the effect of obesity on insulin resistance in pregnancy: a comparison of Asian, South Asian, and Caucasian women. J. Clin. Endocrinol. Metab., 91, 1, 2006.
  28. Thyfault J.P. et al.: Gestational diabetes is associated with depressed adiponectin levels. J. Soc. Gynecol. Investig., 12, 41, 2005.
  29. Tsai P.J. et al. Maternal plasma adiponectin concentrations at 24 to 31 weeks of gestation: negative association with gestational diabetes mellitus. Nutrition, 21, 11-12, 2005.
  30. Vitoratos N. et al.: Serum adiponectin during pregnancy and postpartum in women with gestational diabetes and normal controls. Gynecol. Endocrinol., 24, 11, 2008.
  31. Weyer C. et al.: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol. Metab., 86, 5, 2001.
  32. Wulan S.N., Westerterp K.R., Plasqui G.: Ethnic differences in body composition and the associated metabolic profile: a comparative study between Asians and Caucasians. Maturitas., 65, 4, 2010
  33. Yang W.S. et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J. Clin. Endocrinol. Metab., 86, 8, 2001.


prev next



August 2020

Mon Tue Wed Thu Fri Sat Sun
          01 02
03 04 05 06 07 08 09
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30